Cp. Denton et al., SYSTEMIC-SCLEROSIS - CURRENT PATHOGENETIC CONCEPTS AND FUTURE-PROSPECTS FOR TARGETED THERAPY, Lancet, 347(9013), 1996, pp. 1453-1458
Although there is no cure for systemic sclerosis, the disease is certa
inly treatable. And the more that is understood of its pathogenesis, t
he better the prospects for treatment. Excessive collagen deposition i
n the skin and viscera is responsible for the morbidity and mortality.
The immune system plays a critical role in setting up the fibrotic pr
ocess, but impaired regulation of collagen gene expression probably un
derlies the persistence of fibrosis. The development of effective anti
fibrotic drugs, in particular agents that inhibit transcription factor
s involved in the activation of type I collagen genes, is likely to be
the way forward for treatment of the later stages of diffuse systemic
sclerosis, with immunomodulatory therapy for the earlier stages.